Published in Pulm Circ on March 01, 2016
Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med (2013) 5.22
Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A (1977) 4.90
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov (2006) 2.84
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest (2012) 2.82
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation (2011) 2.48
First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J (2009) 2.04
NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol (2009) 1.81
Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol (2008) 1.43
Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J (2010) 1.28
Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol (2010) 1.10
Riociguat: first global approval. Drugs (2013) 0.97
Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol (2007) 0.91
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.76
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.76
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption. Pulm Circ (2016) 0.76
Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulm Circ (2016) 0.76
Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study. Pulm Circ (2016) 0.75
Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women. Pulm Circ (2016) 0.75
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. Pulm Circ (2015) 0.75
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam. Pulm Circ (2016) 0.75
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.75
Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment. Pulm Circ (2016) 0.75
Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food. Pulm Circ (2016) 0.75
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respir Med (2017) 0.75